Vaxart (VXRT) Competitors

Solid Biosciences (NASDAQ:SLDB) and Vaxart (NASDAQ:VXRT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, community ranking, profitability, institutional ownership and media sentiment.

Do analysts prefer SLDB or VXRT?

Solid Biosciences presently has a consensus price target of $14.90, suggesting a potential upside of 209.45%. Vaxart has a consensus price target of $3.00, suggesting a potential upside of 665.31%. Given Vaxart's higher probable upside, analysts clearly believe Vaxart is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	0 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.23
Vaxart	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community believe in SLDB or VXRT?

Vaxart received 29 more outperform votes than Solid Biosciences when rated by MarketBeat users. However, 69.46% of users gave Solid Biosciences an outperform vote while only 65.47% of users gave Vaxart an outperform vote.

Company	Underperform	Outperform
Solid Biosciences	Outperform Votes 282 69.46%	Underperform Votes 124 30.54%
Vaxart	Outperform Votes 311 65.47%	Underperform Votes 164 34.53%

Which has more risk and volatility, SLDB or VXRT?

Solid Biosciences has a beta of 2.22, suggesting that its share price is 122% more volatile than the S&P 500. Comparatively, Vaxart has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500.

Does the media favor SLDB or VXRT?

In the previous week, Solid Biosciences had 3 more articles in the media than Vaxart. MarketBeat recorded 8 mentions for Solid Biosciences and 5 mentions for Vaxart. Vaxart's average media sentiment score of 0.85 beat Solid Biosciences' score of 0.74 indicating that Vaxart is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaxart	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has stronger valuation & earnings, SLDB or VXRT?

Vaxart has higher revenue and earnings than Solid Biosciences. Solid Biosciences is trading at a lower price-to-earnings ratio than Vaxart, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	$8.09M	46.14	-$96.01M	-$2.99	-1.61
Vaxart	$47.40M	1.89	-$82.46M	-$0.27	-1.45

Do insiders and institutionals hold more shares of SLDB or VXRT?

81.5% of Solid Biosciences shares are held by institutional investors. Comparatively, 18.0% of Vaxart shares are held by institutional investors. 1.9% of Solid Biosciences shares are held by insiders. Comparatively, 2.9% of Vaxart shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Is SLDB or VXRT more profitable?

Solid Biosciences has a net margin of 0.00% compared to Vaxart's net margin of -431.61%. Solid Biosciences' return on equity of -58.75% beat Vaxart's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-58.75%	-47.84%
Vaxart	-431.61%	-110.46%	-62.78%

Summary

Solid Biosciences beats Vaxart on 11 of the 19 factors compared between the two stocks.